Syndax Pharmaceuticals Inc SNDX

NAS: SNDX | ISIN: US87164F1057   20:53
22,03 USD (+0,75%)
(+0,75%)   20:53

1 mei 2024 · Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024 · Persbericht

10 april 2024 · Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum · Persbericht

8 april 2024 · Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session · Persbericht

5 april 2024 · Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

28 maart 2024 · Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia · Persbericht

26 maart 2024 · Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia · Persbericht

18 maart 2024 · Syndax Announces Appointment of Steven Closter as Chief Commercial Officer · Persbericht

1 maart 2024 · Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

27 februari 2024 · Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update · Persbericht

26 februari 2024 · Syndax Announces Participation at Two Upcoming Investor Conferences · Persbericht

20 februari 2024 · Syndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024 · Persbericht

2 februari 2024 · Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

1 februari 2024 · Syndax Announces Participation at Two Upcoming Investor Conferences · Persbericht

5 januari 2024 · Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

2 januari 2024 · Syndax Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference · Persbericht

2 januari 2024 · Syndax Highlights Recent Updates and Anticipated 2024 Milestones · Persbericht

19 december 2023 · Syndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares · Persbericht

15 december 2023 · Syndax Announces Pricing of $200 Million Public Offering of Common Stock · Persbericht

14 december 2023 · Syndax Announces Proposed $150 Million Public Offering of Common Stock · Persbericht

12 december 2023 · Syndax Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting · Persbericht

Mijn selecties